Health Condition 1: C00-D49- Neoplasms
Conditions
Interventions
Intervention1: Paclitaxel: The patients will be administered paclitaxel as per standard chemotherapy protocol according to age, diagnosis, Chemotherapy treatment schedule as for example, For Carcinoma
Sponsors
All India Institute of Medical Sciences Rishikesh
Eligibility
Inclusion criteria
Inclusion criteria: •All chemotherapy naïve patients of malignancy. •Patients of malignancy planned to be treated with paclitaxel. •Patients of malignancy considered fit for chemotherapy will be enrolled in this study •Patients above 18 years of age •Patients willing to provide written informed consent
Exclusion criteria
Exclusion criteria: •Deranged renal function (serum creatinine level >= 1.5 mg/dL), •Concomitant radiotherapy for primary or metastatic sites; •Any other drugs known to induce or inhibit CYP3A4 or CYP2C8 enzyme
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess interpatient variability of CYP2C8 and CYP3A4 activities in chemotherapy naïve cancer patients planned to be treated with paclitaxelTimepoint: 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess adverse drug reactions in chemotherapy naïve cancer patients during paclitaxel infusion. Timepoint: 3 months;To assess interpatient pharmacokinetic variability of paclitaxel in chemotherapy naïve cancer patients. Timepoint: 3 months | — |
Countries
India
Contacts
Public ContactDr Puneet Dhamija
All India Institute of Medical Sciences, Rishikesh
Outcome results
None listed